Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Takehiro, Taninaga"'
Publikováno v:
Translational Psychiatry, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Insomnia is highly comorbid in patients with psychiatric disorders, including depression, bipolar disorder, and substance use disorders, and should be treated as an independent condition. Dual orexin receptor antagonists (DORAs) have been in
Externí odkaz:
https://doaj.org/article/ab8a3f457ec3400ea66278dd7ff36b2a
Autor:
Taro Kishi, Maika Nishida, Michinori Koebis, Takehiro Taninaga, Kenzo Muramoto, Naoki Kubota, Margaret Moline, Kenji Sakuma, Makoto Okuya, Ikuo Nomura, Nakao Iwata
Publikováno v:
Neuropsychopharmacology Reports, Vol 41, Iss 4, Pp 450-458 (2021)
Abstract Most conventional insomnia medications are gamma‐aminobutylic acid receptor agonists. However, physical dependence is a concern and one of the major limiting factors for long‐term treatment. The dual orexin receptor antagonists, suvorexa
Externí odkaz:
https://doaj.org/article/e1c3cd06cd9f45a8a585f4644d879cd0
Autor:
Yuichi, Inoue, Maika, Nishida, Naoki, Kubota, Michinori, Koebis, Takehiro, Taninaga, Kenzo, Muramoto, Kohei, Ishikawa, Margaret, Moline
Publikováno v:
Journal of Clinical Sleep Medicine. 19:519-528
Patients with chronic insomnia may respond differently to therapeutic modalities. This study examined differences in response of individuals with two insomnia phenotypes: short sleep duration (I-SSD,6 hours) and normal sleep duration (I-NSD, ≥6 hou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7ee486815ff47fed20560370a081f7f
https://doi.org/10.5664/jcsm.10378
https://doi.org/10.5664/jcsm.10378
Autor:
Margaret Moline, Makoto Okuya, Takehiro Taninaga, Nakao Iwata, Kenzo Muramoto, Michinori Koebis, Ikuo Nomura, Maika Nishida, Taro Kishi, Naoki Kubota, Kenji Sakuma
Publikováno v:
Neuropsychopharmacology Reports
Most conventional insomnia medications are gamma‐aminobutylic acid receptor agonists. However, physical dependence is a concern and one of the major limiting factors for long‐term treatment. The dual orexin receptor antagonists, suvorexant and le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c19e5bc56db988660805f4504e7c3a7d
http://europepmc.org/articles/PMC8698673
http://europepmc.org/articles/PMC8698673